GILEAD SCIENCES revenue for the last year amounted to 22.83 B CHF, the most of which — 22.83 B CHF — came from its highest performing source at the moment, Innovative Medicines, the year earlier bringing 25.23 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought GILEAD SCIENCES 16.37 B CHF, and the year before that — 17.46 B CHF.